{"url_path":"/sec/qncx/8-k/2026-05-21/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-21","source_url":"https://www.sec.gov/Archives/edgar/data/1662774/0001193125-26-234858-index.html","accession_number":"0001193125-26-234858","cik":"0001662774","ticker":"QNCX","issuer_name":"Quince Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1662774/0001193125-26-234858-index.html","primary_entity_key":"0001662774","primary_entity_name":"Quince Therapeutics, Inc."},"word_count":183,"has_tables":true,"body_markdown":"Item 8.01.\n\nOther Events.\n\nAs previously disclosed, on March 17, 2026, Quince Therapeutics, Inc. (the “Company”) received a notice from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company had failed to maintain a minimum market value of listed securities (“MVLS”) of $50,000,000 over the previous 30 consecutive business days, as required for continued listing on The Nasdaq Global Market under Nasdaq Listing Rule 5450(b)(2)(A).\n\nOn May 20, 2026, the Company received a letter from the Staff stating that, based on the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, which reported stockholders’ equity of $15,672,000, the Company complies with Nasdaq Listing Rule 5450(b)(1)(A). Accordingly, the Company has regained compliance with Nasdaq’s continued listing requirements and this matter is now closed.\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \nQuince Therapeutics, Inc.\n\n \n\n \nBy:\n \n\n/s/ Dirk Thye\n\nDate: May 21, 2026\n \n\n \nName:\n \nDirk Thye\n\n \n\n \nTitle:\n \nChief Executive Officer"}